Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has voluntarily disclosed that its 100% subsidiary, Samsung Biologics America, Inc., resolved to acquire 100% shares of US-based Human Genome Sciences Inc. from GSK for approximately KRW 413.6B to secure local drug substance manufacturing facilities.
📊 [Key Disclosure Details & Financial Figures]
- Subsidiary Name: Samsung Biologics America, Inc. (100% subsidiary of Samsung Biologics)
- Target Company (Issuer): Human Genome Sciences Inc. (Nationality: USA, Core Business: Pharmaceutical manufacturing)
- Number of Acquired Shares & Ownership Ratio: 800 shares (100% stake)
- Acquisition Amount: KRW 413,616,000,000 (KRW 413.6B / USD 280,000,000)
- Applied Exchange Rate: USD/KRW 1,477.20 (Initial base rate on December 19, 2025)
- Samsung Biologics Total Assets: KRW 17,336,296,349,511 (Based on end-2024 consolidated financial statements)
- Acquisition Amount to Total Assets Ratio: 2.39%
- Acquisition Method: Cash acquisition
- Purpose of Acquisition: Acquiring local manufacturing facilities in the US to respond to long-term local demand in the US
- Subsidiary Decision Date (CEO Approval Date): December 19, 2025
- Other Important Investment Details:
- The contract entails acquiring 100% equity of Human Genome Sciences Inc. from GSK, including its US drug substance production facilities, assets, and liabilities.
- The final acquisition amount will be determined upon final Deal Closing, with a correction disclosure to be issued later.
- Expected acquisition date is unconfirmed as of filing due to regulatory approval procedures, and will be updated via correction disclosure once confirmed.
- Financial summaries for the target company are omitted as it is not subject to statutory audit requirements.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verifying Correction Disclosures Upon Final Deal Closing and Regulatory Approval
This voluntary disclosure covers an acquisition where the final purchase price and expected transaction date depend on regulatory approvals and final Deal Closing.
Checking for future correction disclosures confirming the finalized closing date and adjusted purchase price is crucial for verifying the practical completion of the US manufacturing facility acquisition.
Relevant progress and finalized numbers can be verified in upcoming correction disclosures regarding the ‘Decision on Acquisition of Shares and Equity Securities of Other Corporations’.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
